<DOC>
	<DOC>NCT02644486</DOC>
	<brief_summary>To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.</brief_summary>
	<brief_title>A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Clinical diagnosis of obesity diagnosed ORG by renal biopsy LDL&gt;3.37mmol/L Proteinuria 0.53.5g/d eGFR (CKDEPI formula) &gt; 30ml/min Other concomitant renal diseases Endocrine or druginduced obesity; Type 2 diabetes eyes or obvious microscopic hematuria; Swallowing difficulty / severe gastrointestinal dysfunction intestinal obstruction; severe arrhythmia; Hypophosphatemia (&lt;0.7mmol/L); allergic to Sevelamer Carbonate unable to well cooperate Females who are in the period of gestation or lactation, or refuse to use contraception; participated in other clinical trial of drug within three months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>